Stocks › NTLA
Intellia Therapeutics, Inc.
NTLA·Nasdaq·
United States·USD
United States·USD$12.37
-0.38 (-2.98%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
NTLA
Intellia Therapeutics, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NTLAS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of NTLA by members of U.S. Congress · 16 on record
Whale Activity
Position changes in NTLA reported for 2026-06-30 by 13 tracked institutional filers
- Increased7
- New1
- Held0
- Decreased1
- Closed0
- No prior filing4
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 15.4M | $260.7M | increased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7.3M | $124.1M | increased |
| D. E. Shaw & Co., Inc. | 6.4M | $109.0M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $102.0M | increased |
| TWO SIGMA INVESTMENTS, LP | 5.2M | $88.6M | increased |
| Amova Asset Management Americas, Inc. | 2.9M | $49.0M | — |
| RENAISSANCE TECHNOLOGIES LLC | 1.4M | $23.7M | new |
| MILLENNIUM MANAGEMENT LLC | 491.2K | $8.3M | increased |
| Point72 Asset Management, L.P. | 398.5K | $6.7M | increased |
| Casdin Capital, LLC | 355.0K | $6.0M | — |
| GFS Advisors, LLC | 130 | $5.8M | — |
| CITADEL ADVISORS LLC | 164.7K | $2.8M | decreased |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by NTLA insiders, by quarter · Form 4
Recent Insider Transactions
516 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Dube Michael PVP, Chief Accounting Officer | Sale | −1,864 | $12.43 | $23K | Oct 2, 2026 | Form 4 ↗ |
| LEONARD JOHN MPresident and CEO · Director | Sale | −2,785 | $13.00 | $36K | Aug 21, 2026 | Form 4 ↗ |
| LEONARD JOHN MPresident and CEO · Director | Sale | −19.9K | $12.60 | $251K | Aug 20, 2026 | Form 4 ↗ |
| Dulac Edward J IIIEVP, Chief Financial Officer | Sale | −8,111 | $11.25 | $91K | Jul 22, 2026 | Form 4 ↗ |
| Dulac Edward J IIIEVP, Chief Financial Officer | Sale | −4,677 | $18.00 | $84K | Jul 2, 2026 | Form 4 ↗ |
| Dube Michael PVP, Chief Accounting Officer | Sale | −2,641 | $16.78 | $44K | Jul 1, 2026 | Form 4 ↗ |
| GOODMAN JESSEDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| CHASE WILLIAM JDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Verwiel FrankDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Keresty GeorgiaDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Goff BrianDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Cohen Fred EDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| Bhanji MunaDirector | Grant / award | +9,200 | $0.00 | $0 | Jun 9, 2026 | Form 4 ↗ |
| BASTA JAMESEVP, General Counsel | Sale | −1,211 | $13.78 | $17K | Mar 2, 2026 | Form 4 ↗ |
| Clark ElianaEVP, Chief Technical Officer | Sale | −607 | $13.78 | $8K | Mar 2, 2026 | Form 4 ↗ |
| LEONARD JOHN MPresident and CEO · Director | Grant / award | +156.4K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| BASTA JAMESEVP, General Counsel | Grant / award | +46.1K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| Lebwohl DavidEVP, Chief Medical Officer | Grant / award | +9,943 | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| Dulac Edward J IIIEVP, Chief Financial Officer | Grant / award | +61.3K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
| Schultes Birgit CEVP, Chief Scientific Officer | Grant / award | +39.2K | $0.00 | $0 | Mar 1, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding NTLA · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| ARK Innovation ETF ARK ETF Trust | 10.0M | $106.7M | 1.92% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 5.8M | $97.4M | 0.91% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 4.3M | $72.5M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.5M | $59.6M | 0.07% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 3.1M | $52.6M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS | 1.8M | $30.4M | 0.06% | Jun 30, 2026 |
| ARK Genomic Revolution ETF ARK ETF Trust | 2.7M | $28.5M | 1.83% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $27.2M | 0.03% | Jun 30, 2026 |
| Select Biotechnology Portfolio Fidelity Select Portfolios | 1.9M | $26.9M | 0.51% | May 31, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 1.3M | $21.4M | 0.15% | Jun 30, 2026 |
Mutual funds and ETFs whose N-PORT filings list NTLA's shares (CUSIP 45826J105), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming intellia therapeutics as client
No lobbying filings found naming Intellia Therapeutics, Inc. as the client.
- CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2022 Q1—
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2022 Q1—
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q4 · HCR$30K
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q3 · HCR$30K
Filing ↗ - CROSSROADS STRATEGIES, LLCINTELLIA THERAPEUTICS · 2021 Q2 · HCR$30K
Filing ↗
Government Contracts
Federal awards to Intellia Therapeutics, Inc. · USAspending
No federal contract awards found for Intellia Therapeutics, Inc..
U.S. Patents
Recent USPTO applications naming Intellia Therapeutics, Inc.
No USPTO patent applications found for Intellia Therapeutics, Inc..
Annual Financials
From NTLA's 10-K filings · XBRL
No annual XBRL figures on record for NTLA. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
No stock splits in NTLA's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsSep 8, 2026
EDGAR ↗ - 8-K · Items 1.01, 2.03, 7.01, 9.01Material agreement · Direct financial obligation · Reg FD disclosureSep 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 6, 2026
EDGAR ↗ - 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsJun 15, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 10, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗
About Intellia Therapeutics, Inc.
From SEC EDGAR company records
Industry (SIC 2835)In Vitro & In Vivo Diagnostic Substances
SectorHealthcare
HeadquartersCAMBRIDGE, MA
IncorporatedDE
SEC CIK0001652130 ↗